Cover Image

Sodium-glucose cotransporter 2 inhibitors: glucose lowering against other hypoglycemic agents

Background: The treatment of diabetes remains challenging over the decades, even after - the introduction of numerous novel drugs of different classes. Most patients with type 2 diabetes require a combination of multiple agents and eventually the use of insulin. The newest antidiabetic drugs, possib...

Full description

Saved in:
Bibliographic Details
Main Authors: Avranas, Konstantinos (Author) , Imprialos, Konstantinos (Author) , Stavropoulos, Konstantinos (Author) , Lales, Georgios (Author) , Manafis, Alexandos (Author) , Skalkou, Anastasia (Author) , Kihm, Lars Philipp (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Cardiovascular & hematological disorders, drug targets
Year: 2018, Volume: 18, Issue: 2, Pages: 94-103
ISSN:2212-4063
DOI:10.2174/1871529X18666180206160838
Online Access:Verlag, lizenzpflichtig, Volltext: https://dx.doi.org/10.2174/1871529X18666180206160838
Verlag, lizenzpflichtig, Volltext: http://www.eurekaselect.com/159601/article
Get full text
Author Notes:Konstantinos Avranas, Konstantinos Imprialos, Konstantinos Stavropoulos, Georgios Lales, Alexandos Manafis, Anastasia Skalkou and Lars Kihm
Description
Summary:Background: The treatment of diabetes remains challenging over the decades, even after - the introduction of numerous novel drugs of different classes. Most patients with type 2 diabetes require a combination of multiple agents and eventually the use of insulin. The newest antidiabetic drugs, possibly with the most pleiotropic actions after metformin are the sodium-glucose cotransporter 2 (SGLT-2) inhibitors (SGLT-2i). This class has a unique mechanism inhibiting the glucose reabsorption in the proximal tubule of the kidney.
Physical Description:Online Resource
ISSN:2212-4063
DOI:10.2174/1871529X18666180206160838

Similar Items